Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol HUMA
- Company Humacyte, Inc.
- Price $0.71
- Changes Percentage 14.29
- Change 0.0886
- Day Low $0.61
- Day High $0.8
- Year High $2.93
- Year Low $0.55
- Market Cap $235,200,000
- Price Avg 50 EMA (D) $0.86
- Price Avg 200 EMA (D) $1.21
- Exchange NASDAQ
- Volume 5,479,378
- Average Volume 7,464,488
- Open $0.63
- Previous Close $0.62
- EPS -0.63
- PE -2.22
- Earnings Announcement 2026-08-10 04:00:00
- Shares Outstanding $168,000,000
Company brief: HUMACYTE, INC. (HUMA )
- Healthcare
- Biotechnology
- Dr. Laura E. Niklason M.D., Ph.D.
- https://www.humacyte.com
- US
- N/A
- 12-01-2020
- US44486Q1031
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
